TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00971100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study: NCT02944058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiloc nail
Description: Intervention is surgery with Multiloc nail

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Philos plate
Description: Intervention is surgery with Philos plate
Study: NCT04086199

Intervention type: PROCEDURE
Intervention: Lumbar discectomy
Description: Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.

Intervention type: PROCEDURE
Intervention: Lumbar discectomy
Description: Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
Study: NCT01184924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Arthritis Foundation Tai Chi Program
Description: The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
Study: NCT02352753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous (SC) injection.
Study: NCT04120272

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
Study: NCT04345679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
Study: NCT00607867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LoBAG30 diet
Description: A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
Study: NCT04130672

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy
Description: After hot packing nasopharyngeal irrigation with 50 C saline

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy
Description: After cold packing nasopharyngeal irrigation with 22 C saline
Study: NCT03005548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine
Description: In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning.
Study: NCT04361578

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance elastography
Description: All patients enrolled will receive magnetic resonance elastography of the brain.
Study: NCT03962075

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic paravaginal repair
Description: Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
Study: NCT00126776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: case management
Description: case/self management for COPD vs usual care

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: usual care for COPD
Study: NCT00479856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Chemotherapy
Study: NCT01749150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir + ritonavir
Description: 125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir + ritonavir
Description: 125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000-1200 mg orally daily in divided doses, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000-1200 mg orally daily in divided doses, 24 weeks
Study: NCT04611087

Intervention type: BEHAVIORAL
Intervention: Discussion
Description: Attend focus groups

Intervention type: OTHER
Intervention: Interview
Description: Attend interviews

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03874884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: During dose escalation doses of olaparib that can be administered are 50mg BD D2-15, 100mg BD D2-15, 150mg BD D2-15, 200mg BD D2-15,250mg BD D2-15, 300mg BD D2-15, 200mg BD D4-14, 300mg BD D-4-14 or 400mg D-4-18 of a 42 day cycle for up to 6 cycles.~The recommended phase 2 dose of olaparib will be used in 2 consecutive dose expansion cohorts. The first cohort will received the recommended phase 2 dose of Olaparib on D4-14 of a 42 day cycle. Patients enrolled in the second dose expansion cohort will receive Olaparib continuously from cycle 1 day -4 to cycle 6 day 42.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA
Description: A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for up to 6 cycles.
Study: NCT01440816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Study: NCT03776201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
Study: NCT02396563

Intervention type: PROCEDURE
Intervention: epidural analgesia

Intervention type: DRUG
Intervention: Ropivacaine
Study: NCT01770236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
Study: NCT02858947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aelite Flo
Description: Microhybrid flowable composite

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: x-tra base
Description: Bulk-fill flowable composite
Study: NCT01331980

Intervention type: DEVICE
Intervention: Peripheral quantitative computed tomography (pQCT)
Description: A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit

Intervention type: DEVICE
Intervention: Peripheral quantitative computed tomography (pQCT)
Description: A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit

Intervention type: DEVICE
Intervention: Dual X-ray absorptiometry (DXA)
Description: A total body DXA scan will be conducted at a single study visit

Intervention type: DEVICE
Intervention: Dual X-ray absorptiometry (DXA)
Description: A total body DXA scan will be conducted at a single study visit
Study: NCT00609570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NanoGreens
Description: fruits and vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Whey

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium pills
Description: CA
Study: NCT03944408

Intervention type: PROCEDURE
Group type: OTHER
Intervention: stent implantation
Description: stent implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent implantation
Description: stent implantation
Study: NCT01351116

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBR plus HDRIB
Description: EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
Study: NCT02647931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy for Muscle Tension Dysphagia
Description: Voice therapy for Muscle Tension Dysphagia
Study: NCT03391258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Regeneration with GLAM technique
Description: Bone regeneration with GLAM technique in full arch implant supported rehabilitation
Study: NCT03947333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care
Description: The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
Study: NCT02702076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Description: Continuous subcutaneous infusion of apomorphine during waking day
Study: NCT01350128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide HFA Inhalation Aerosol
Description: Taken as 2 inhalations of the 17 µg per actuation strength MDI QID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Matching placebo to PT001 MDI administered as two puffs BID for 7 days
Study: NCT01283126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: euglycemic and hypoglycemic clamp
Description: Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
Study: NCT00779103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin Subcutaneous Implant
Description: histrelin subcutaneous 50 mg implant
Study: NCT02559869

Intervention type: DRUG
Intervention: [18F] GE-180
Description: PET Tracer Ligand
Study: NCT02692859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine
Description: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
Study: NCT01552239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT/IGRT, Tumor resection, Brachytherapy
Description: All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection
Study: NCT04033159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYN101
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYN101
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYN101
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
Study: NCT01841593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Isentress 400mg tablet taken twice daily
Study: NCT02909556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement via transfemoral access
Study: NCT02290288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Study: NCT02020005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored 2mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-flavored 2mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-flavored 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored nicotine inhaler

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-flavored nicotine ihaler
Study: NCT02702076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous subcutaneous infusion of placebo during waking day
Study: NCT01873274

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK-7 containing capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: basic yogurt enriched with MK-7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrient-enriched yogurt with MK-7
Study: NCT03520361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Description: Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
Study: NCT03466476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consensus TracPatch
Description: Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
Study: NCT00218673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Description: groups sessions, 8
Study: NCT02882555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study: NCT03520361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L PEG/Asc
Description: Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
Study: NCT00761891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewable aspirin
Description: chewable aspirin 81mg daily for 2 weeks
Study: NCT02882555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study: NCT02103894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807 ([18F]MNI-777)
Description: All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
Study: NCT00449956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride (+) timolol maleate
Description: Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: timolol maleate
Description: timolol maleate 0.5%, 8-week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: timolol maleate
Description: timolol maleate 0.5%, 8-week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: dorzolamide hydrochloride
Description: dorzolamide hydrochloride 1%, 8-week
Study: NCT00046735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT